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Xenotropic murine leukemia virus-related virus (XMRV) infection was incorrectly associated with prostate
cancer and chronic fatigue syndrome (CFS) in recent years. In this forum, we discuss the story of XMRV
and how we can apply lessons learned here to inform the debate surrounding cancers associated with
human endogenous retroviruses (HERVs).For nearly 50 years, the study of natural
and laboratory retrovirus infection in a
number of animal models has played a
central role in our understanding of the
molecular mechanisms of cancer. Onco-
genes, or sequences derived from normal
cell genes (protooncogenes) that are
incorporated into retrovirus genomes
in ways that allow them to transform
normal cells, provided virologists with
the simple means to obtain genetic proof
that expression of a single gene could
be sufficient to establish and maintain
the transformed state. Many of the onco-
genes identified in these animal virus
cancer models were later shown to play
important roles in human cancer as well,
although modified by mutation or DNA
rearrangement rather than incorporation
into a virus. In addition to incorporation
into a virus genome, oncogenes can also
be created by integration of the viral
DNA provirus in the vicinity of a protoon-
cogene, causing it to come under the
control of the viral transcriptional control
elements encoded within the long termi-
nal repeats (LTRs) at each proviral end.
Early studies in these models revealed
that many oncogenic retroviruses origi-
nally identified as exogenously transmis-
sible agents, including murine leukemia
virus (MLV) and mouse mammary tumor
virus (MMTV), can also be transmitted
genetically as inherited, or endogenous,
proviruses, derived by infection of a
germline cell of an ancestor of the
modern day species. Although creation
(and subsequent fixation) of an endoge-
nous provirus is a rare event, the genomes
of mice, humans, and indeed all verte-
brates, as well as many invertebrates,
have accumulated large numbers ofthese elements, amounting for 8% or
more of the total genomic DNA (Stoye,
2012). Most of these endogenous viruses
(ERVs) are very old and riddled with dele-
tions and mutations, rendering them
nonfunctional. However, in some species,
including mice, infection leading to new
ERVs is also quite recent and continues
to this day.
Early in the last century, inbred mouse
strains were developed to study the
genetics of certain diseases, including
cancer. In one case, exemplified by AKR
and other strains, all mice develop T cell
lymphoma at about 6 months of age.
In another, as in the C3H strain, female
mice routinely develop mammary carci-
noma after the second or third litter.
In both cases, the generation of these
strains involved the happenstance com-
bination of specific endogenous provi-
ruses, in addition to host factors affect-
ing permissiveness to infection. For AKR
mice, infectious endogenous MLV is
expressed starting in late gestation. Infec-
tion of a large number of cells in the devel-
oping fetus allows recombination of this
virus with two other related endogenous
viruses to give rise to a virus that can
efficiently infect the thymic T cell targets,
of which a few become transformed and
go on to become a lymphoma (Stoye,
2012). In the mouse mammary carcinoma
model, the situation is a bit different.
Initial studies revealed that MMTV trans-
mission either from mother to offspring
via milk or via an endogenous provirus,
which can be expressed and spread
as infectious virus to mammary epithe-
lium, resulted in occasional integration
adjacent to a protooncogene as the key
event in oncogenesis.Cell Host & Microbe 1In addition to providing insights into
the mechanism of human cancer, study
of these animal models also stimulated
interest into whether these or similar
viruses might be important causes of
cancer in humans as well. Starting in the
early 1970’s, frequent reports appeared
describing a variety of studies purporting
to show the association of various can-
cers with MLV or MMTV-like viruses
(as reviewed by Weiss, 1999). With the
notable exception of human T cell leuke-
mia virus, all viruses reported in these
studies were cases of mistaken identity
for one reason or another, and the
mistakenly identified viruses came to
be known as ‘‘human rumor viruses.’’
In the following section, we discuss two
recently studied examples of human
cancer-associated endogenous viruses.
The first, although completely disproven
as a cause of human disease, provides
some important lessons; the book on
the second is not yet closed.
XMRV
In the early years of this century, it was
found that a gene associated with an
aggressive form of prostate cancer
encoded ribonuclease L (RNase L), a
well-known mediator of the interferon
antiviral response, implying a viral etiology
for some cases of this disease. In 1996, it
was reported that when PCR-amplified
cDNA made from prostate tumor RNA
was hybridized to a microarray containing
a collection of viral DNA sequences
(the virochip), a positive signal was found
only for MLV sequences. Following up
on this observation, researchers were
able to isolate a virus capable of infecting
human prostate cancer cells as well as5, March 12, 2014 ª2014 Elsevier Inc. 255
Figure 1. Recombinant Origin of XMRV
The uninfected CWR22 tumor was passaged serially in nude mice. Sometime prior to 1996, the xenograft
was infected by an infectious recombinant derived from the two noninfectious XMLVs preXMRV-1 and
preXMRV-2. In 1992, the 22rv1 cell line was derived from this tumor and has been passaged in culture
ever since. This image is reprinted with permission from Delviks-Frankenberry et al. (2012).
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Since the sequence of this virus showed
it to be closely related to xenotropic
MLV (XMLV), but distinct from all known
isolates, it was named xenotropic MLV-
related virus, or XMRV (Urisman and
Molinaro, 2012). Further support for a
role for XMRV in prostate cancer came
from studies claiming detection by
immunofluorescence of XMRV-related
antigens on primary tumor cells (Schla-
berg et al., 2009) and from the observa-
tion that high levels of a nearly identical
virus were produced by a prostate cancer
cell line named 22Rv1.
Scientific and public attention to XMRV
picked up substantially several years
later with the report of its isolation from
blood cells of patients with chronic fatigue
syndrome (CFS) (Silverman et al., 2011).
Interestingly, isolates from CFS patients
afflicted in different parts of the US and
in different years were almost identical
in sequence to XMRV and one another,
raising the possibility that the virus was
derived from an endogenous provirus
of wild mice that occasionally caused
zoonotic outbreaks among human popu-
lation. By contrast, a different group re-
ported using PCR to detect a variety of
XMRV-related sequences in a collection
of CFS samples collected years before,
while more recently collected blood
samples from unaffected subjects were256 Cell Host & Microbe 15, March 12, 2014negative (Lo et al., 2012). These reports
created considerable excitement, not
only among virologists who had spent
much of their career studying MLVs and
related viruses, but also among long-
suffering CFS patients, who were encour-
aged to believe that there might be
an eventual answer to their mysterious
affliction.
Unfortunately, the picture painted by
these initial findings began to fall apart
fairly quickly, as laboratory after labora-
tory failed to reproduce the initial findings
associating any MLV-like virus with pros-
tate cancer or CFS. Studies using PCR
analysis, immunoassay, and attempted
viral isolation all came up negative again
and again (Delviks-Frankenberry et al.,
2012). Finally, a carefully designed,
blinded multicenter study using the as-
says designed by the investigators who
published the original positive reports
came to a clear conclusion. All of the
original investigators agreed to a lack
of association of XMRV, or any other
MLV-like virus, to CFS or prostate cancer,
with no evidence for infection of any
human with XMRV.
Further study revealed the reason for
the false positive PCR results: sporadic
contamination of laboratory reagents
with mouse DNA, which could be de-
tected in most positive samples using an
even more sensitive assay for a highlyª2014 Elsevier Inc.repeated murine retroelement. In most
cases, the specific source of the con-
tamination was not established, but
there was one exception. PCR assay kits
sold by one company include a mouse
monoclonal antibody (and incidentally,
mouse DNA) to inhibit activity of the
DNA polymerase until after the reaction
is heated. As it happens, the enzyme
used in the initial virochip assay that
detected MLV in prostate cancer samples
was from the same source.
Sporadic mouse DNA contamination
provided a satisfying explanation for the
positive PCR results, but what was the
source of XMRV itself? The key to this
puzzle turned out to be the 22Rv1 cell
line mentioned above (Figure 1). Around
1992, a tumor line named CWR22 was
established from a prostate cancer by
xenotransplantation into nude mice. The
CWR22 tumor was maintained by serial
nude mouse transplant for 7 years and
spawned several sublines, one of which
was 22Rv1. 22Rv1 has been grown
continuously ever since, distributed to
laboratories worldwide, and become
popular as a prostate cancer model.
Indeed, between its isolation in 1999 and
the discovery that it was producing
XMRV about 10 years later, there are no
fewer than 134 papers reporting its use
in many laboratories, none of which were
aware that cultures contain about 1011
particles of virus per ml. Even in virology
laboratories, there is occasional cross-
contamination of cultures by viruses
under study. It seems virtually certain
that contamination of other cultures
by infectious XMRV would have occurred
when the cultures were handled by
investigators who were unaware that
their cultures were infected.
How did the 22Rv1 cells get infected in
the first place? Initially, it was thought
that the answer was simply that the
patient who donated the original CWR22
tumor was infected. Samples from the
original tumor are no longer available
to test this possibility; fortunately, DNA
samples from the tumor at various
stages of xenograft passage were avail-
able for analysis with highly specific PCR
assays (Paprotka et al., 2011). XMRV
was readily detected in the latest tumor
passage, from 1996, but not in earlier
ones (Figure 1). Thus, the original tumor
was not infected, but became so after
about 6 years of passage.
Figure 2. HERV-K (HML-2) and Primate Evolution
Syncytins are env genes encoded by other retrovirus groups that have been co-opted by their mammalian host for use in normal placenta formation. Virus image
reprinted with permission from Kurth and Bannert (2010). Scale bar, 100 nm.
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of the infection. Although no provirus
resembling XMRV was present, there
were two proviruses, named preXMRV-1
and preXMRV-2, that were present at
low levels and must have come from cells
derived from the nude mouse host. Each
of these two proviruses was nearly iden-
tical to XMRV over about half its length,
and a recombinant essentially identical
to 22Rv1 could easily be derived. Trans-
fection experiments showed that neither
preXMRV-1 nor preXMRV2 was infec-
tious, but that infectious recombinant
virus can readily be isolated following
cotransfection of cells with both (Delv-
iks-Frankenberry et al., 2012). Frequent
recombination is a feature of retrovirus
replication and must be the mechanism
by which XMRV arose originally.
XMRV was the latest in a long line of
human rumor viruses and received by
far the most publicity. It will probably not
be the last, but the lessons are clear.
The bar for accepting reports of novel
viruses, particularly retroviruses, with
human disease must be set very high.
The presence of widespread infectious
endogenous viruses in many animal spe-
cies and very large numbers of copies
of endogenous virus DNA in all verte-
brates creates unprecedented potential
for unwitting contamination of clinical
and experimental samples and the re-
agents used to analyze them with everincreasing sensitivity. Punctilious atten-
tion to the inclusion of safeguards against
this kind of contamination, particularly
inclusion of true, contemporaneous
controls, is essential to ensure the integ-
rity of assays for novel cancer viruses.
Only in this way can the field be moved
from rumor to fact.
HERV-K (HML-2)
Although XMRV was debunked as a
human pathogen, there remains the
possibility that a human endogenous
retrovirus (HERV) can cause disease.
There are many HERV families, and the
majority of HERV sequences have accu-
mulated mutations and deletions over
the course of primate evolution. In
contrast to examples currently found in
mice, no HERV has been shown to be
infectious as is, although infectious re-
combinants can be generated (Ruprecht
et al., 2008). Many HERVs now exist as
solo LTRs, the result of LTR-LTR recom-
bination that leads to the loss of the
remainder of the provirus. Within a HERV
group, solo LTRs can outnumber pro-
viruses by a factor of ten (Subramanian
et al., 2011). Importantly, some HERVs
have retained LTRs with transcriptional
activity and open reading frames (ORFs)
for retroviral genes, signifying their endur-
ing biological relevance.
The most recently integrated group
of HERVs, named HERV-K (HML-2)Cell Host & Microbe 1(Figure 2), comprises at least 91 provi-
ruses with full or partial coding capacity
and 944 solo LTRs (Subramanian et al.,
2011). Taken together, they maintain
ORFs for all retroviral genes needed for
infectivity, and some have been shown
to form intact, but noninfectious, particles
in the placenta as well as in germ cell
tumors and melanoma (Kurth and Ban-
nert, 2010). This group was named for
their presumed use of the lysine tRNA
during reverse transcription (HERV-K)
and their similarity to MMTV (human
MMTV-like) (Hohn et al., 2013).
The relatively recent entry of HML-2
proviruses into the human genome and
their sequence preservation has led to
speculation about whether these pro-
viruses can encode an infectious retro-
virus. The provirus K113 (on chromosome
19p12) appears to retain full coding
capacity for all retroviral genes; however,
it was not replication competent in vitro
(Hohn et al., 2013). Potentially, recom-
bination among as few as three HML-2
proviruses could lead to the production
of an infectious retrovirus, essentially the
same mechanism that created XMRV
(Hohn et al., 2013). Also, it remains
possible that an exogenous form of
HML-2 is still spreading at a low fre-
quency within the population.
The similarity of HML-2 to MMTV, and
its potential for generation of infectious
virus, has prompted steady research into5, March 12, 2014 ª2014 Elsevier Inc. 257
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terms of carcinogenesis. Expression of
ERVs, including HML-2 and other groups,
is silenced in most healthy tissues
(except for placenta) due to the repressive
effects of CpG methylation (Stoye, 2012).
In malignant tissues and cell lines, by
contrast, HML-2 expression as RNA, pro-
tein, and even viral particles is commonly
seen. The pathogenic effects of such
expression in humans are unknown.
The first clear association of HML-2
expression with human disease came
with the discovery of HML-2-encoded
viral particles observed to bud from
germ cell tumors (GCTs) (Ruprecht et al.,
2008). These viral particles are not infec-
tious, and their functional significance
is unclear. In studies of GCT patients,
reports of HML-2 RNA, Env, and Gag
protein expression are abundant, and
antibody responses against these anti-
gens are observed in 50%–80% of
patients (Ruprecht et al., 2008).
Similar to GCTs, melanomas and
breast cancers are also highly associated
with HML-2 expression. In melanoma,
approximately 16%–22% of patients
develop an antibody response against
HML-2 Env and Gag proteins (Hohn
et al., 2013). Retroviral particles have
also been observed in melanoma cell
lines, and claims of their infectivity remain
to be validated (Ruprecht et al., 2008).
Breast cancer similarly shows high-level
HML-2 expression in the form of mRNA
and protein, where 66% of primary breast
cancers exhibit HML-2 Env expression
(Cegolon et al., 2013). It has been sug-
gested, with some support from trans-
genic mouse models, that expression
of HML-2 Env protein, the accessory
protein Rec, or the Np9 protein encoded
by a common deletion mutant may act
like retroviral oncogenes and play a
direct role in oncogenesis, but a causal
role for these commonly expressed genes
will be hard to prove.
Whether or not HML-2 expression is
related to the etiology of cancer, it can
clearly have a significant effect on the
tumor phenotype. Treatment of breast
cancer cells with HML-2 Env-specific
antibodies blocks their proliferation and
induces apoptosis in vitro (Cegolon
et al., 2013). Antibody treatment also
reduces the growth of xenografted tu-
mors in mice in vivo. Intriguingly, meta-
stasis to the lymph nodes is more likely258 Cell Host & Microbe 15, March 12, 2014to occur in tumors expressing HML-2
Env. The applicability of this finding to
human breast cancer and metastasis is
still being investigated. Since at least
one HML-2 Env has preserved its fuso-
genicity needed for entry into target cells
and, like other retroviruses, may encode
immunosuppressive activity (Ruprecht
et al., 2008), expression could contribute
to oncogenesis by fusing neighboring
cells and causing genomic instability
or by allowing for tumor immune evasion
by expression of this surface glycopro-
tein. While these properties are readily
recognized in other retroviral Env pro-
teins, they are not well established for all
HML-2 proviruses with env ORF.
It is unclear if HML-2 expression during
cancer implicates a role in the disease
process or is merely a consequence of
changes in the transcriptional environ-
ment typical of cancer cells. The evidence
provided thus far consists of reports of
HML-2 RNA, protein, and particle ex-
pression during cancers (as well as
normal development), but does not
ascribe a definitive role for HML-2 activity
in contributing to cancer etiology in
humans. Evidence for direct involvement
of HML-2 in cancer could come from
several directions. First and foremost,
if a replication-competent exogenous
variant circulating at a low rate exists
or a recombination event occurs to
create a functional HML-2 virus (as
happened to form XMRV), then it should
be possible to isolate virus and establish
a correlation between infection and
cancer incidence. Recombination to
form an infectious virus would most likely
occur when expression of HML-2 pro-
viruses is elevated, potentially in the
events that lead to cancer onset or during
cancer progression. If infection by an
HML-2 virus is responsible for some
proportion of cancers or contributes to
the disease process, the viral sequences
can be isolated and identified from the
tumor.
Even if an infectious virus cannot be
readily isolated, the presence of a new
HML-2 integration site in cancerous, but
not healthy, tissue provides irrefutable
evidence of retroviral infection and would
strongly imply a direct role for infection
in the disease process. Since retroviral
DNA integration is at more or less random
sites, if the integration leads to tumor
formation, then the tumor would repre-ª2014 Elsevier Inc.sent a clonal population of cells marked
with the same oncogenic integration
and would be relatively straightforward
to detect. Furthermore, as in the animal
models discussed above, consistent tar-
geting of one or a few genes in different
tumors could provide significant mecha-
nistic insight into the oncogenic process.
Alternate methods of HML-2 oncogen-
esis not involving new infection of target
cells are possible but much harder to pin
down. env, rec, and np9 could act as
oncogenes that contribute to cancer
progression. Further, endogenous HML-
2 proviruses could contribute splice donor
or acceptor sites and sites of transcrip-
tional regulation in the flanking LTRs.
HML-2 proviruses and solo LTRs that
are not fully silenced could then promote
expression of neighboring genes or alter-
native transcripts that make use of the
proviral LTRs and splice sites. Addition-
ally, proviruses and solo LTRs provide
sites of identity on the same chromosome
or between different chromosomes that
could lead to genomic rearrangements
(Feschotte and Gilbert, 2012). These
large-scale genomic changes could be
detected and connected to associated
disease processes.
While all of these alternative mecha-
nisms are plausible contributors to cancer
induction and progression, they are not
virologically unique, in that they could
apply to host-derived genes as well.
Only a smoking gun, like isolation of an
infectious HML-2 virus or detection of
novel integration events affecting proto-
oncogene expression, will clearly elevate
these interesting elements into the ranks
of human tumor viruses.
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